Overview

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Status:
Terminated
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Symphogen A/S